28/1 2026
Abstract: This technical guide examines the two dominant terminal sterilization modalities employed in medical gauze manufacturing — gamma irradiation utilizing cobalt-60 radioisotopes and ethylene oxide (EtO) gas sterilization. Through analysis of dosimetric parameters, microbial inactivation kinetics, polymer degradation mechanisms, and residual toxicity profiles, this document provides validation scientists and quality assurance professionals with the technical foundation required for sterile process selection and qualification per ISO 11137 and ISO 11135 standards. For a complete guide to medical gauze procurement including sterilization requirements, see our Medical Gauze Complete Buyer's Guide.
Gamma irradiation sterilization exploits high-energy electromagnetic radiation emitted during the radioactive decay of cobalt-60 (60Co), a synthetic radioisotope produced through neutron activation of stable cobalt-59 in nuclear reactors. The decay process generates two characteristic gamma photons with energies of 1.17 MeV and 1.33 MeV, yielding a combined energy output of 2.50 MeV per disintegration event. These photons possess exceptional penetration capability, enabling delivery of sterilizing doses to densely packed medical device configurations and permitting sterilization of product in final packaging—a critical advantage termed "parametric release."
Industrial gamma irradiators typically operate with cobalt-60 source activities ranging from 1 to 5 million Curies (37-185 PBq), housed in concrete-shielded facilities designed to ISO safety specifications. Product pallets traverse the irradiation field via automated conveyor systems, with exposure duration calculated to deliver the validated absorbed dose based on predetermined dosimetric mapping and product density characterization. The omnidirectional emission pattern of gamma rays from the 60Co source necessitates careful geometric optimization to achieve dose uniformity ratios (Dmax/Dmin) within acceptable validation parameters.
The internationally recognized standard sterilization dose for medical devices is 25 kGy, derived from the seminal Artandi and Van Winkle study (1959), which determined this dosage provides a 40% safety margin above the minimum killing dose for the most radiation-resistant microorganisms encountered in healthcare product bioburden. However, operational gamma sterilization processes typically deliver absorbed doses within the 25-50 kGy range to accommodate density variations and ensure minimum dose achievement throughout heterogeneous product loads.
The absorbed dose—measured in kilograys (kGy), where 1 kGy equals 1 kJ of energy absorbed per kilogram of matter—quantifies the energy deposition that produces the sterilization effect. ISO 11137-1 specifies two primary validation methodologies for establishing sterilization dose: Method 1 (bioburden-based approach) and Method 2 (VDmax verification dose approach). The VDmax method enables substantiation of 15 kGy, 25 kGy, or seven additional intermediate doses (17.5, 20, 22.5, 27.5, 30, 32.5, 35 kGy) through microbiological testing of product samples exposed to sub-lethal verification doses.
Sterility Assurance Level (SAL) Requirement: The target sterility assurance level for terminal sterilization is 10-6, representing a theoretical probability of not more than one viable microorganism per million sterilized units. This overkill approach ensures that even products with elevated pre-sterilization bioburden achieve the requisite SAL through validated dose delivery. The relationship between bioburden (N0), D-value (decimal reduction dose), and required dose (D) follows logarithmic inactivation kinetics: D = D10 × log(N0/Nf) where Nf = 10-6.
Gamma photons exert their bactericidal effect through ionization of water molecules within microbial cells, generating reactive oxygen species (ROS) including hydroxyl radicals (•OH), superoxide anions (O2-), and hydrogen peroxide (H2O2). These highly reactive intermediates inflict catastrophic damage to critical biomolecules, with deoxyribonucleic acid (DNA) serving as the primary lethal target. Direct ionization events cause single-strand breaks (SSBs) and double-strand breaks (DSBs) in the phosphodiester backbone, while indirect radical-mediated damage produces base modifications, DNA-protein crosslinks, and clustered lesions that overwhelm cellular repair mechanisms.
The ionizing radiation also disrupts cellular membranes through lipid peroxidation cascades and denatures essential enzymatic proteins by oxidizing sulfhydryl groups and aromatic amino acid residues. Bacterial spores, particularly Bacillus pumilus (E601 strain), demonstrate the highest radiation resistance due to DNA protective mechanisms including α/β-type small acid-soluble proteins (SASPs), reduced water content, and efficient DNA repair enzymes. Consequently, spore-forming organisms serve as worst-case biological indicators (BIs) for gamma sterilization validation studies.
While gamma irradiation effectively eliminates microbial contamination, the identical ionization mechanisms that destroy pathogens can inflict detrimental alterations to polymer matrices, particularly cellulose-based materials such as cotton gauze. The high-energy photons induce two competing reactions in polymeric systems: chain scission (random cleavage of covalent bonds) and crosslinking (formation of inter-chain covalent bridges). For cellulose, the predominant radiation-induced transformation is random degradation via glycosidic bond cleavage, resulting in progressive reduction of molecular weight and corresponding deterioration of mechanical properties.
The degradation mechanism proceeds through formation of alkoxy radicals (RO•) on the polymer backbone, which abstract hydrogen atoms from adjacent C-H bonds, initiating chain scission events. The extent of degradation correlates linearly with absorbed dose—at 25 kGy, cotton gauze experiences approximately 15-20% reduction in tensile strength, while doses exceeding 40 kGy may produce 30-40% strength loss with concomitant yellowing (chromophore formation) and embrittlement. The molecular mass distribution factor, quantifiable through gel permeation chromatography (GPC), provides objective assessment of radiation-induced polymer degradation.
Critical Validation Consideration: Product qualification must include accelerated aging studies demonstrating that sterilized gauze maintains functional performance specifications throughout labeled shelf life. Real-time aging at 23°C ± 2°C / 50% ± 5% RH combined with accelerated aging at 55°C per ASTM F1980 provides predictive data on radiation-induced polymer degradation progression during post-sterilization storage.
Ethylene oxide (C2H4O, CAS 75-21-8) is a three-membered heterocyclic epoxide characterized by exceptional chemical reactivity arising from substantial ring strain (approximately 105 kJ/mol). This colorless, flammable gas at ambient conditions (boiling point 10.7°C) functions as a potent alkylating agent, attacking nucleophilic sites on biological macromolecules to disrupt cellular metabolism and replication. The small molecular size (molecular weight 44.05 g/mol) and amphiphilic character confer extraordinary penetration capability through porous materials, polymer matrices, and complex device geometries—properties that established EtO as the preeminent low-temperature sterilization modality for heat-sensitive medical devices.
Industrial EtO sterilization systems employ either 100% ethylene oxide or mixtures with inert diluent gases (typically 8.5-10% EtO with 90-91.5% CO2 or hydrochlorofluorocarbons) to mitigate explosion hazards. Pure EtO vapor becomes flammable at concentrations of 3-100% by volume in air, necessitating explosion-proof sterilization chamber design and continuous environmental monitoring.
Unlike the single-parameter gamma irradiation process, EtO sterilization requires precise orchestration of multiple interdependent variables across four sequential operational phases. The complete cycle duration typically extends 2.5-4 hours excluding post-sterilization aeration, with each phase contributing critical process control elements.
Products destined for EtO sterilization undergo mandatory preconditioning in controlled-environment chambers maintained at 30-50°C and 50-80% relative humidity for 12-72 hours prior to gas exposure. This phase serves three essential functions: (1) equilibration of product temperature to sterilization cycle specifications, eliminating thermal gradients that could compromise process reproducibility; (2) hydration of microbial cells to optimal moisture content, as water molecules facilitate EtO penetration through cell walls and participate in alkylation chemistry; and (3) moisture absorption by hygroscopic packaging materials to prevent excessive moisture loss during subsequent chamber evacuation.
Upon completion of preconditioning, product loads transfer to the sterilization chamber — a sealed, pressure-rated vessel constructed from 316L stainless steel. The gas introduction sequence commences with deep vacuum evacuation (typically to 25-60 Pa absolute pressure) to remove residual air, which otherwise would consume EtO through oxidation reactions and dilute sterilant concentration. EtO gas then enters the chamber through distribution manifolds, targeting concentrations of 450-1200 mg/L with 600-800 mg/L representing the optimal efficacy range.
The exposure phase maintains stable temperature (37-63°C, typically 45-60°C), EtO concentration, and relative humidity for a predetermined duration (1-6 hours, typically 3-4 hours for standard cycles). Elevating temperature from 45°C to 55°C can reduce required exposure time by approximately 40-50% while maintaining equivalent SAL achievement, provided humidity and gas concentration remain within validated ranges. Such modifications necessitate complete revalidation per ISO 11135-1 requirements.
At exposure completion, the sterilization chamber undergoes multiple evacuation and air flush cycles (typically 4-8 repetitions) to remove EtO residuals from chamber atmosphere and product surfaces. Products exit the sterilization chamber with substantial absorbed EtO within porous materials, necessitating extended aeration phases addressed in subsequent sections.
The bactericidal, virucidal, fungicidal, and sporicidal efficacy of ethylene oxide derives from its function as an alkylating agent that irreversibly modifies essential cellular constituents. The strained epoxide ring undergoes facile nucleophilic ring-opening reactions, with biological nucleophiles including sulfhydryl groups (-SH) on cysteine residues, amino groups (-NH2) on proteins and nucleic acid bases, carboxyl groups (-COOH), and hydroxyl groups (-OH) on various biomolecules.
When targeting DNA, EtO alkylates primarily at N-7 of guanine and N-3 of adenine, generating promutagenic lesions that block DNA replication and transcription. Protein alkylation disrupts enzymatic function through modification of active site residues. The cumulative effect produces the observed broad-spectrum antimicrobial activity, with Bacillus atrophaeus (formerly B. subtilis var. niger) serving as the biological indicator organism for EtO validation.
Fractional Cycle Validation: Per ISO 11135-1, EtO sterilization validation employs fractional cycle methodology wherein product samples inoculated with biological indicators (typically 106 B. atrophaeus spores) undergo exposure to various fractions (0.25×, 0.50×, 0.75×, 1.0×) of the proposed sterilization time. Logarithmic survivor curves derived from fraction cycle testing enable calculation of overkill cycle parameters that deliver 12-log reduction beyond naturally occurring bioburden, ensuring 10-6 SAL achievement.
The significant challenge differentiating EtO sterilization from gamma irradiation is management of toxic residual chemicals that persist within and on product surfaces following the sterilization cycle. Ethylene oxide readily reacts with polymer materials containing chlorine substituents, forming stable ethylene chlorohydrin (ECH, 2-chloroethanol). Additionally, unreacted EtO physically absorbs into porous materials and dissolves in polymer matrices, creating reservoirs requiring extended degassing periods before products achieve safe residual levels.
The toxicological profile of ethylene oxide establishes it as a human carcinogen (IARC Group 1), mutagen, reproductive toxin, and acute respiratory irritant. ECH, the primary EtO reaction product, demonstrates comparable toxicity profiles including mutagenicity and neurotoxicity. These hazards necessitate stringent residual limits for sterilized medical devices based on exposure route, contact duration, and patient population.
ISO 10993-7 establishes maximum allowable limits for EtO and ECH residuals based on device categorization by exposure type and duration:
Medical gauze, classified as a short-term external communicating device with direct tissue contact, must demonstrate EtO residuals below 250 ppm and ECH residuals below 250 ppm prior to market release. Residual quantification employs gas chromatography with flame ionization detection (GC-FID) or headspace GC-mass spectrometry (HS-GC-MS) following standardized extraction protocols.
Post-sterilization aeration removes absorbed EtO and ECH through diffusion-controlled desorption enhanced by elevated temperature and forced air exchange. Conventional ambient aeration at 20°C requires 7-14 days to achieve acceptable residual levels. Industrial practice employs mechanical aeration in purpose-designed rooms maintained at 50-60°C with continuous air exchange rates of 4-20 room volumes per hour, reducing degassing duration to 8-12 hours for most medical devices.
Kingphar Forced Aeration: Kingphar's forced aeration rooms incorporate advanced airflow optimization with variable-temperature zones (45-65°C gradient programming) and real-time environmental monitoring that reduce residual clearance times 30-40% below industry standard performance. Computational fluid dynamics (CFD) modeling ensures uniform air distribution across pallet loads, eliminating cold spots that could delay EtO desorption, while maintaining residual levels averaging 40-60% below ISO 10993-7 maximum allowable limits.
We offer customized sterilization options based on your market's regulatory requirements. Request a quote for our EO sterilized gauze sponges or gamma irradiated packs today.
| Parameter | Gamma Irradiation (60Co) | Ethylene Oxide (EtO) |
|---|---|---|
| Sterilization Mechanism | Ionization producing DNA strand breaks, protein oxidation, membrane lipid peroxidation | Alkylation of nucleophilic sites on proteins and nucleic acids |
| Penetration Capability | Excellent — photons penetrate dense materials, metals, liquids; sterilization in final packaging | Excellent for porous/gas-permeable materials; poor for impermeable barriers, sealed liquids |
| Material Compatibility | Degradation risk for polymers (chain scission); yellowing of cellulose; acceptable for metals, glass | Excellent polymer compatibility; ECH formation with chlorinated polymers |
| Cycle Time | Hours to days depending on dose rate; no aeration required | 2.5-4 hours sterilization + 12-72 hours preconditioning + 8-48 hours aeration = 1-5 days total |
| Residual Concerns | None — process leaves no chemical residues | Significant — EtO and ECH residuals require extensive degassing; strict limits per ISO 10993-7 |
| Temperature Requirements | Ambient; no special thermal considerations | 45-60°C sterilization temperature; contraindicated for heat-sensitive materials |
| Bioburden Tolerance | High — overkill approach accommodates bioburden up to 103-104 CFU per product at 25 kGy | Moderate — requires bioburden control; elevated bioburden necessitates cycle extension |
| Validation Standard | ISO 11137-1/2/3 | ISO 11135-1/2 |
| Biological Indicator | Bacillus pumilus spores (E601 strain), D10 ≈ 2.5-3.5 kGy | Bacillus atrophaeus spores (ATCC 9372), Dvalue varies with cycle parameters |
| Environmental Impact | No emissions; cobalt-60 source requires secure storage and eventual disposal as nuclear waste | Toxic emissions require abatement systems; flammability hazard |
| Capital Investment | High — irradiation facility ($10-50M); often contract sterilization model | Moderate — chamber acquisition ($200K-2M); facility modifications; aeration infrastructure |
| Regulatory Complexity | Moderate — dosimetric validation, dose distribution mapping, ongoing dosimetry program | High — residual testing, biological validation, worker safety, emission control |
Industry Best Practice for Medical Gauze: The majority of medical gauze manufacturers employ ethylene oxide sterilization as the preferred terminal sterilization modality, particularly for products where maintenance of textile strength and avoidance of discoloration constitute critical quality attributes. Cotton gauze derives its absorbency, conformability, and tensile strength from the molecular architecture of cellulose polymer chains — characteristics vulnerable to radiation-induced degradation yet essentially unaffected by EtO alkylation chemistry. For surgical gauze sponges used for wound packing or hemostasis, in-situ fragmentation from radiation degradation could necessitate secondary surgical intervention — making EtO the preferred choice for these applications.
The concept of Sterility Assurance Level represents the probability that a unit subjected to validated sterilization conditions harbors viable microorganisms post-treatment. The internationally recognized standard SAL of 10-6 signifies that the theoretical probability of non-sterility does not exceed one in one million units.
Validation of terminal sterilization processes requires comprehensive characterization of pre-sterilization microbial contamination — termed bioburden — present on or within product units prior to sterilization exposure. Bioburden enumeration follows standardized protocols per ISO 11737-1, employing validated extraction methods followed by aerobic culture incubation and colony enumeration. For medical gauze, typical pre-sterilization bioburden ranges from 101 to 103 colony-forming units (CFU) per product when manufactured under appropriate environmental controls.
Critical Validation Principle: Sterilization validation does not demonstrate that every unit in a production lot is sterile. Rather, validation proves that the process, when consistently applied to product meeting defined bioburden specifications and manufactured under validated environmental conditions, achieves the statistical probability of sterility defined by the target SAL. This distinction underpins the parametric release concept, wherein product is released based on demonstration that specified process parameters were achieved, without conducting sterility testing on the release lot itself.
The ISO 11137 standard (Parts 1-3) governs gamma sterilization validation, covering requirements for development, validation, and routine control; establishing sterilization dose; and dosimetric guidance. The ISO 11135-1 standard governs EtO validation, incorporating additional complexities arising from multivariate process parameters and residual management.
Critical documentation for both modalities includes: dose distribution mapping studies, dosimeter calibration certificates traceable to national standards, biological indicator challenge test reports, and product performance testing post-sterilization. For EtO, residual clearance validation per ISO 10993-7 must also be included. These records form the technical foundation for regulatory submissions (510(k), CE Technical Files) and facility audits.
Mandatory revalidation triggers include product modifications, process parameter changes, facility changes, supplier changes affecting bioburden or material sensitivity, and scheduled periodic intervals (typically every 3-5 years minimum).
Kingphar supplies EO-sterilized and gamma-irradiated medical gauze with full sterilization validation documentation, batch-specific CoA, and residual test reports for GCC, European, and North American markets.
Request a Sample or QuoteVisit our blog center for the full archive of medical supply guides and industry news.
Back to Blog CenterA: USP Type VII (20×12) and 19×15 are the industry standards for general surgery. However, for high-exudate management or precision hemostasis, 28×24 is preferred due to its 13-16× fluid retention capacity and superior tensile strength.
A: Degreasing (scouring) removes natural waxes from cotton fibers, reducing the contact angle to near 0°. Without proper degreasing, gauze remains hydrophobic, extending absorption time from <10 seconds to several minutes, which can be critical during active bleeding.
A: Woven 100% cotton gauze is superior for debridement and packing because of its structural integrity and capillary wicking. Non-woven gauze is often softer and less linting, making it suitable for sensitive wound surfaces, but it lacks the mechanical strength required for deep surgical packing.
A: Failure is typically caused by residual sizing agents (like starch) or incomplete removal of natural lipids. If the gauze does not submerge within 10 seconds, it indicates a breakdown in the scouring and bleaching protocols during manufacturing.
Kingphar Medical Group New’s 06/10 2026 No results See all results Table of Contents Incoming Quality Inspection (IQI) for Medical Consumables: Complete Guide Procurement Quality ·
Kingphar Medical Group New’s 06/10 2026 No results See all results Table of Contents Incoterms for Medical Supplies: FOB vs CIF vs DDP Explained (2026) Procurement
Kingphar Medical Group New’s 21/9 2026 No results See all results Table of Contents Inventory Management · Procurement Guide Medical ConsumablesShelf Life & ExpiryManagement Guide Shelf
Kingphar Medical Group New’s 31/8 2026 No results See all results Table of Contents Procurement Guide · Tender Writing How to Write Medical ConsumableTender SpecificationsThat Win
Kingphar Medical Group New’s 18/8 2026 No results See all results Table of Contents Procurement Guide · Import & Customs Medical ConsumablesImport Documentation:The Complete Checklist A
Kingphar Medical Group New’s 7/8 2026 No results See all results Table of Contents Procurement Guide · Import & Customs Medical Consumables HS Codes:Classification & ImportDuty
Cooperation, innovation and win-win
Don’t miss our future updates! Get Subscribed Today!
